Inclusion of Digestible Surfactants in Solid SMEDDS Formulation Removes Lag Time and Influences the Formation of Structured Particles During Digestion
- 371 Downloads
Solid self-microemulsifying drug delivery systems (SMEDDS) have received considerable attention in recent times attempting to overcome the drawbacks of liquid SMEDDS. Earlier literature reports on solid SMEDDS have focussed on formulation development; however, the digestibility and propensity for self-assembly of the digested components with endogenous bile salts and phospholipids are unknown. Therefore, as a starting point, previously reported solid SMEDDS containing Gelucire® 44/14 (GEL) and the non-digestible surfactants, Vitamin E TPGS (TPGS) and Lutrol® F 127 (F 127), were prepared, and their dispersion and digestion behaviours were studied using an in vitro lipolysis model, coupled with small-angle X-ray scattering (SAXS) to determine the formed colloidal structures during digestion in real time. GEL alone was digested (89%) and formed a lamellar phase (Lα). When surfactants were added at a 40:60% w/w lipid to surfactants ratio, digestion was inhibited with a significant lag time being evident. However, increasing the fraction of GEL to 50% w/w enabled digestion with reduced lag time. The substitution of the non-digestible surfactants with digestible surfactants, sucrose esters S-1670 (S-1670) and Span® 60 (S-60), eliminated the digestion lag time, and the formation of colloidal structures was more similar to that of GEL alone.
KEY WORDSin vitro lipolysis lipid digestion non-digestible and digestible surfactants small-angle X-ray scattering solid SMEDDS
Kapilkumar’s Ph.D. research was supported by Gattefossé (Saint-Priest, France). The SAXS experiments were undertaken at the SAXS/WAXS beamline at the Australian Synchrotron, Victoria, Australia. Ben Boyd is funded under the Australian Research Council Future Fellowship scheme, and the project was partly funded by the ARC Discovery Grant scheme.
COMPLIANCE WITH ETHICAL STANDARDS
CONFLICT OF INTEREST
Vincent Jannin is an employee of Gattefossé (Saint-Priest, France), who manufactures the Gelucire® 44/14 used in this study.
- 1.Vonderscher J, Meinzer A, editors. Rationale for the development of Sandimmune Neoral. Transplantation proceedings; 1994.Google Scholar
- 6.Truong DH, Tran TH, Ramasamy T, Choi JY, Lee HH, Moon C, et al. Development of solid self-emulsifying formulation for improving the oral bioavailability of Erlotinib. AAPS PharmSciTech. 2015:1-8.Google Scholar
- 20.Singh SK, Vuddanda PR, Singh S, Srivastava AK. A comparison between use of spray and freeze drying techniques for preparation of solid self-microemulsifying formulation of valsartan and in vitro and in vivo evaluation. BioMed research international. 2013;2013.Google Scholar
- 28.P. Thipsay JM, M. Repka hot melt extrusion technology for the formulation of solid self microemulsifying drug delivery systems. AAPS 2014.Google Scholar
- 30.Porter CJ, Kaukonen AM, Taillardat‐Bertschinger A, Boyd BJ, O’Connor JM, Edwards GA, et al. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride‐based oral lipid formulations of poorly water‐soluble drugs: studies with halofantrine. J Pharm Sci. 2004;93(5):1110–21.CrossRefPubMedGoogle Scholar
- 32.Kossena GA, Boyd BJ, Porter CJ, Charman WN. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water‐soluble drugs. J Pharm Sci. 2003;92(3):634–48.CrossRefPubMedGoogle Scholar
- 39.Mitsubishi Kagaku Foods Corporation J. http://www.mfccojp/english/s1670.htm
- 40.National Library of Medicine TdN. https://www.toxnetnlmnihgov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+778
- 42.Trull A, Tan K, Tan L, Alexander G, Jamieson N, editors. Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Transplantation proceedings; 1994.Google Scholar
- 44.Khan J, Hawley A, Rades T, Boyd BJ. In situ lipolysis and synchrotron small-angle X-ray scattering for the direct determination of the precipitation and solid-state form of a poorly water-soluble drug during digestion of a lipid-based formulation. Journal of Pharmaceutical Sciences.Google Scholar
- 51.Vitamin E TPGS, properties and applications. Eastman, USA.Publication EFC-226A(October 1998).Google Scholar
- 52.Szűts A. Study of the applicability of sucrose esters in hot-melt technology. PhD Faculty of Pharmacy, Department of Pharmaceutical Technology University of Szeged. 2003.Google Scholar
- 57.Goddeeris C, Van den Mooter G. Free flowing solid dispersions of the anti-HIV drug UC 781 with Poloxamer 407 and a maximum amount of TPGS 1000: investigating the relationship between physicochemical characteristics and dissolution behaviour. Eur J Pharm Sci. 2008;35(1–2):104–13.CrossRefPubMedGoogle Scholar
- 59.Shah DO. Macro- and microemulsions: theory and applications: ACS Publications.Google Scholar